Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743084 | 0.80 | OPRL1 (0.46) | OPRL1 | |
| SCHEMBL2037274 | 0.78 | OPRL1 (0.30) | OPRL1 | |
| SCHEMBL2689713 | 0.72 | ALDH1A1 (0.33) | OPRL1 | |
| SCHEMBL19508120 | 0.69 | ALOX15 (0.36) | OPRL1 | |
| SCHEMBL628684 | 0.67 | SCN5A (0.35) | SCN5A | |
| SCHEMBL28232732 | 0.66 | — | — | |
| SCHEMBL2688222 | 0.65 | ALDH1A1 (0.34) | OPRL1 | |
| SCHEMBL2690052 | 0.65 | TRPV1 (0.36) | — | |
| SCHEMBL2689390 | 0.64 | TRPV1 (0.42) | OPRL1 | |
| SCHEMBL6245643 | 0.64 | ALOX15 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338603-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120108642-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2012-05-03 | — | — | US | disclosed |
| US-8084616-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2215061-A2 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090124671-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055629-A2 | CYCLOHEXENEAMIDE DERIVATIVES AND THEIR USE AS TRPV1 ANTAGONIST | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108642-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV5, TRPV3 | OPRL1 7/4885SCN5A 280/4885 |
| US-20090124671-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV5, TRPV3 | OPRL1 7/4885SCN5A 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.